Citius Oncology (CTOR) said Friday that Dr. Reddy's Laboratories (RDY) agreed to a partial deferral without penalty of a milestone payment by Citius that was triggered upon the US Food and Drug Administration's approval of the Lymphir cancer therapy.
The milestone payment was due Sept. 9, Citius said in a filing with the US Securities and Exchange Commission.
The company said that except for the partial deferral of the milestone payment, its September 2021 asset purchase agreement with Dr. Reddy's remains in full force and effect.
CTOR shares were up 3.7% in recent Friday trading while RDY shares were climbing 0.4%.
Price: 80.51, Change: +0.25, Percent Change: +0.32
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。